Nucleic acid aptamers in cancer research, diagnosis and therapy

Ma, Haitao; Liu, Jinping; Ali, M. Monsur; Mahmood, M. Arif Iftakher; Labanieh, Louai; Lü, Min; Iqbal, Samir M.; Zhang, Qun; Zhao, Weian; Wan, Yuan

doi:10.1039/c4cs00357h

Cited by 218 publications

(119 citation statements)

References 282 publications

Supporting

Mentioning

119

Contrasting

Order By: Relevance

“…In many ways aptamers can be superior to antibodies as they are just as selective and have identical binding affinities but are also non-immunogenic, more easily synthesized and can be generated against practically any target. In cancer, aptamers can be used in a variety of ways, including cancer diagnostics and testing, as a therapeutic agent for cancer and as active targeting agents for drug delivery (Lao et al 2015, Ma et al 2015.…”

Section: Aptamersmentioning

confidence: 99%

The state-of-play and future of platinum drugs

Apps

Choi

Wheate

2015

Endocrine-Related Cancer

224

141

View full text Add to dashboard Cite

The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, especially for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas. Since its discovery, five other platin drugs have received approval in various countries. While several new platin drugs are in preclinical development, in the last decade only two new platin drugs have entered clinical trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs. These formulations include their encapsulation with macrocycles to slow and prevent their degradation by proteins and peptides; their attachment to nanoparticles to passively target solid tumours through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumour targeting. These formulation methods have all shown potential but none have yet yielded a new marketable medicine containing a platin drug. The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles. In addition to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.

show abstract

Section: Aptamersmentioning

confidence: 99%

The state-of-play and future of platinum drugs

Apps

Choi

Wheate

2015

Endocrine-Related Cancer

224

141

View full text Add to dashboard Cite

show abstract

“…Aptamers are short, single‐stranded DNA or RNA, which fold into distinct secondary and tertiary structures to bind to targets, such as metal ions, small molecules, proteins, viruses, cells, etc . They possess many distinctive characteristics, including high affinity, small size, low cost, quick and reproducible synthesis, convenient and controllable modification, nontoxicity, etc.…”

Section: Ctc Releasementioning

confidence: 99%

Beyond Capture: Circulating Tumor Cell Release and Single‐Cell Analysis

Sharma

et al. 2019

Small Methods

View full text Add to dashboard Cite

As the most promising “liquid biopsy”, analysis of circulating tumor cells (CTCs) provides noninvasive access to obtain biological information of solid tumors. It not only advances the understanding of the mechanisms underlying tumor metastasis, relapse, and chemoresistance, but also promotes the development of precision medicine. Over the past decade, the rapid advances in micro/nanomaterials and microfluidics have overcome the technical challenges of capturing CTCs, allowing efficient enrichment and sensitive detection. Beyond the capture of CTCs, major challenges of in‐depth CTC analysis are the release of CTCs from capture platforms and the inherent heterogeneity in CTCs. A variety of technologies have now emerged for release and single‐cell analysis of CTCs. This review focuses on recent progress along this direction. First, different release strategies are outlined and discussed, including their design principles and characteristics (merits and limitations). Then, existing methods for single CTC analysis at the genomic, transcriptomic, proteomic, and functional level are summarized. Finally, some perspectives are provided on current development trends, future research directions, and challenges of CTC studies.

show abstract

“…Compared with other ligands, aptamers’ small size, facile chemical synthesis, excellent chemical stability, versatility in structural design and engineering and low immunogenicity enable their widely use in cancer imaging and therapy applications [1]. In recent years, there are growing numbers of aptamers being exploited and applied in various areas including disease diagnosis, clinical therapy, analytical chemistry, food safety, bio-sensing and environmental toxicity detection [2].…”

Section: Introductionmentioning

confidence: 99%

Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy

Chen

Jiang

et al. 2016

IJMS

View full text Add to dashboard Cite

SELEX (systematic evolution of ligands by exponential enrichment) is a process involving the progressive isolation of high selective ssDNA/RNA from a combinatorial single-stranded oligonucleotide library through repeated rounds of binding, partitioning and amplification. SELEX-derived single-stranded DNA/RNA molecules, called aptamers, are selected against a wide range of targets, including purified proteins, live cells, tissues, microorganisms, small molecules and so on. With the development of SELEX technology over the last two decades, various modified SELEX processes have been arisen. A majority of aptamers are selected against purified proteins through traditional SELEX. Unfortunately, more and more evidence showed aptamers selected against purified membrane proteins failed to recognize their targets in live cells. Cell-SELEX could develop aptamers against a particular target cell line to discriminate this cell line from others. Therefore, cell-SELEX has been widely used to select aptamers for the application of both diagnosis and therapy of various diseases, especially for cancer. In this review, the advantages and limitations of cell-SELEX and SELEX against purified protein will be compared. Various modified cell-SELEX techniques will be summarized, and application of cell-SELEX in cancer diagnosis and therapy will be discussed.

show abstract

Nucleic acid aptamers in cancer research, diagnosis and therapy

Cited by 218 publications

References 282 publications

The state-of-play and future of platinum drugs

The state-of-play and future of platinum drugs

Beyond Capture: Circulating Tumor Cell Release and Single‐Cell Analysis

Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About